Phase 2Completed
Everolimus Aging Study (EVERLAST)
Clinical Evaluation of mTORC1 Inhibition for Geroprotection
- Sponsor
- University of Wisconsin, Madison (Academic or other)
- Enrolment
- 106 enrolled
- Conditions
- Aging; Insulin Resistance
- Interventions
- Everolimus 0.5 MG once per day; Everolimus 5 MG once per week; Placebo once per day; Placebo once per week
- Ages
- adults, older adults
- Registry
- NCT05835999
From the registry
The objective of this project is to determine if mTORC1 inhibition by 24 weeks of daily (0.5 mg/day) or weekly (5 mg/week) everolimus can safely improve physiological and molecular hallmarks of aging in humans. Participants who are 55-80 years old and insulin resistant or prediabetic will be randomized to treatment and can expect to be on study for up to approximately 38 weeks. Participants aged 18-35 will not receive the intervention and can expect to be on study for up to approximately 8 weeks.
Primary outcomes
- Metabolic Function: Change in peripheral insulin sensitivity